KUALA LUMPUR (June 11): Based on corporate announcements and news flow today, companies in focus on Monday (June 14) may include: IJM Corp Bhd, Kuala Lumpur Kepong Bhd (KLK), Serba Dinamik Holdings Bhd, Boustead Heavy Industries Corp Bhd (BHIC), Uzma Bhd, Yong Tai Bhd, Reservoir Link Energy Bhd and Sern Kou Resources Bhd.
The National Pharmaceutical Regulatory Agency (NPRA) has approved a clinical study of another Covid-19 vaccine, said Health Director-General Tan Sri Dr Noor Hisham Abdullah
PETALING JAYA: Three thousand Malaysian adults will be invited to participate in the phase three clinical trials for a new vaccine manufactured by Chinese firm Shenzhen Kangtai Biological Products Co Ltd, says the Health Ministry.
Health director-general Tan Sri Dr Noor Hisham Abdullah said the clinical study involving the inactivated vaccine was approved by the National Pharmaceutical Regulatory Division (NPRA) on May 28.
The third phase of the clinical study of this vaccine would be conducted in eight research centres in Malaysia targeting the participation of 3,000 adults aged 18 and above and was expected to take 15 to 19 months, he said.
“The Health Ministry would like to inform that there is an addition of one clinical study, involving the product SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL manufactured by Shenzhen Kangtai Biological Products Co Ltd from China.
PETALING JAYA: Malaysia will participate in phase three clinical trials for a new vaccine manufactured by Chinese firm Shenzhen Kangtai Biological Products Co Ltd, says the Health Ministry.
Health director-general Tan Sri Dr Noor Hisham Abdullah said the clinical study involving the inactivated vaccine was approved by the National Pharmaceutical Regulatory Agency (NPRA) on May 28.
Phase three clinical study of this vaccine will be conducted in eight research centres in Malaysia targeting the participation of 3,000 adults aged 18 years and above and is expected to take 15 to 19 months. The Health Ministry would like to inform that there is an addition of one clinical study, involving the product SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL manufactured by Shenzhen Kangtai Biological Products Co Ltd from China.
Saturday, 05 Jun 2021 05:07 PM MYT
Health director-general Tan Sri Dr Noor Hisham Abdullah during a press conference reporting the daily update on the country’s Covid-19 situation at the Ministry of Health, May 8, 2021. Bernama pic
Follow us on Instagram and subscribe to our Telegram channel for the latest updates.
KUALA LUMPUR, June 5 The National Pharmaceutical Regulatory Agency (NPRA) has approved a clinical study of another Covid-19 vaccine, said Health director-general Tan Sri Dr Noor Hisham Abdullah.
He said the clinical study involving the SARS-CoV-2 Vaccine (Vero Cells), inactivated, 5μg/0.5mL, manufactured by Shenzhen Kangtai Biological Products Co., Ltd. in China was approved on May 28.